Get Involved
Australian & New Zealand Childrens Haematology/Oncology Group

Clinical Trials

HR-NBM study: High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

Solid tumour: High risk neuroblastoma

Status: In Development

The treatment and prognosis (chance of cure) for a child with neuroblastoma is assessed by tests done at time of diagnosis. These tests include a biopsy of the tumour, special molecular tests on the tumour tissue, and investigations to determine whether the tumour has spread and if so, where.  The results of all these tests are then used to decide the “stage” of the tumour (defined by its extent of spread) and the disease “risk” (the chance of disease recurrence).

This study is being done to establish the best treatment for children with neuroblastoma that has a high risk of recurring. Currently, a range of chemotherapy agents and combinations are used to treat children with high risk neuroblastoma. This trial will provide evidence regarding which combinations provide the best outcomes.

 

Disease Stage: Newly diagnosed

Patient Age Range: Over 1 year of age

Recruitment Period: Up to 4 years

Trial Sponsors:

  • International: SIOPEN/ Gustave Roussy
  • National: ANZCHOG

ANZCHOG acknowledges the valuable support of the HR-NBM Study by the Children's Cancer Foundation

logo-childrens-cancer-foundation.jpg